DALLAS, May 12, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.microstockprofit.com/ads/HEB
Hemispherx Biopharma Inc. (HEB) is a developer, maker and distributor of natural immune system drug therapies for the treatment of a variety of viral and immune-based disorders. The Company's new drug therapies include Ampligen, as well as Alferon N Injection. Ampligen is currently under early clinically development for the treatment of Chronic Fatigue Syndrome (CFS). Ampligen's applications also include its use as an adjuvant for the development of therapeutic and preventative vaccines. The Company's Alferon N product is used as an indicator for genital warts. Alferon LDO is currently under development for treating and/or preventing influenza and viral diseases.
Message Board Search for HEB: http://www.boardcentral.com/boards/HEB
In the report, the analyst notes:
"The pharmaceutical industry has underperformed the DJIA by nearly 50% from the market lows of March 9, 2009. Generally, pharmaceutical drug sales tend to be more inelastic during economic slowdowns, but are also much dependent on consumers ability to pay without company-sponsored or other third-party medical plans during periods of high unemployment.
"In the case of HEB, however, successful monetization of its product line lies in the Company's most timely development of its drug candidate, Ampligen, an experimental therapeutic for the H5N1 virus. The PolyI:PolyC12U has been noted by the publication, Therapeutics and Clinical Risk Management, as the lead adjuvant candidate for mucosal vaccines. The publication also mentioned Ampligen was "extremely important" in further studies, as the drug produces "cross-protection" against variant influenza viruses."
To read the entire report visit: www.microstockprofit.com/ads/HEB
See what investors are saying about HEB at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.